Thomas Bock

Thomas Bock's Title

Thomas Bock serves as the Chief Executive Officer (CEO) of Notable Labs. His role involves steering the company towards achieving its mission of advancing patient-focused precision medicine. As CEO, Bock is responsible for strategic decision-making, overseeing operations, and ensuring the company’s growth and success in the biopharmaceutical industry.

Thomas Bock's Company

Thomas Bock leads Notable Labs, a biotechnology company that focuses on utilizing its Predictive Precision Medicine Platform (PPMP) to enhance the effectiveness of clinical trials and treatments. Under Bock's leadership, Notable Labs aims to address urgent unmet medical needs, particularly in the treatment of relapsed/refractory acute myeloid leukemia (AML). The company is currently working on the Volasertib Phase 2 trial, which is anticipated to begin in Q2 2024.

Thomas Bock's Education and Expertise

Thomas Bock holds both an MD and an MBA, providing him with a unique blend of medical and business expertise. His medical background gives him a deep understanding of diseases such as cancer, while his business education equips him with the skills necessary to lead and manage a biotechnology company. Bock’s personal experience with cancer in his family further fuels his commitment to advancing Notable’s patient-focused mission.

Thomas Bock's Background

Thomas Bock's personal connection to cancer, having seen its impact on his own family, drives his dedication to the field of oncology. This personal experience has given him a profound appreciation for Notable's Predictive Precision Medicine Platform (PPMP) and its potential to improve patient outcomes. Before joining Notable Labs, Bock had a distinguished career, welcoming new Board Directors who are seasoned industry leaders with significant achievements in biopharmaceuticals and life sciences.

Thomas Bock's Achievements

Under Thomas Bock's leadership, Notable Labs has made significant strides in the field of precision medicine. One of the notable achievements is the in-licensing of Volasertib, a PLK-1 inhibitor with demonstrated activity in AML and other tumor types. The PPMP's 100% accurate prediction of fosciclopirox’s clinical trial outcome is another milestone, eliminating the need for a 30-patient cohort in the Volasertib program. The upcoming Volasertib Phase 2 trial, set to begin in Q2 2024, represents a significant step forward in addressing the urgent unmet medical needs of patients with relapsed/refractory AML.